Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Devonian Health Group Reports Notice of Allowance for a US Patent Application Covering Use of Thykamine for Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"PurGenesis Technologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Devonian Health Group Announces Positive Topline Results from Phase 2 Clinical trial of Thykamine\u2122 in Mild to Moderate AD","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Devonian Health Group Announces the Journal of Drugs in Dermatology Acceptance for Publication of Thykamine\u2122 Positive Phase 2 Clinical Trial Results in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Devonian Health Group Announces Peer-Reviewed Publication of Thykamine\u2122 Positive Phase 2 Clinical Trial Results in Journal of Drugs in Dermatology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Devonian to Present Thykamine\u2122 Phase 2 Clinical Results at the 6th Dermatology Drug Development Summit for Inflammatory Skin Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Devonian Announces Private Placement of up to $5 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"Devonian Announces Closing of a Private Placement of $1.2 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Devonian Health Group

    Menu

    Devonian Health Group

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Devonian Health Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Devonian Announces Closing of a Private Placement of $1.2 Million

              Details:

              The proceeds will fund the preparation of clinical study programs for PUR0110 (thykamine) in phase 2/3 program of pediatric atopic dermatitis, phase 2 programs of radiodermatitis associated with radiotherapy and in Hand and Foot Syndrome and associated with chemotherapy.

              Lead Product(s): Thykamine

              Therapeutic Area: Dermatology Product Name: PUR0110

              Highest Development Status: Phase II/ Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $1.2 million Upfront Cash: Undisclosed

              Deal Type: Private Placement June 06, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Devonian Health Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Devonian Announces Private Placement of up to $5 Million

              Details:

              The proceeds will fund the clinical study programs for PUR0110 (thykamine) in particular the phase 2/3 program in pediatric atopic dermatitis, the phase 2 programs in radiodermatitis associated with radiotherapy and in Hand and Foot Syndrome and associated with chemotherapy.

              Lead Product(s): Thykamine

              Therapeutic Area: Dermatology Product Name: PUR0110

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: TSX Venture Exchange

              Deal Size: $5.0 million Upfront Cash: Undisclosed

              Deal Type: Private Placement May 19, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Devonian Health Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Devonian to Present Thykamine™ Phase 2 Clinical Results at the 6th Dermatology Drug Development Summit for Inflammatory Skin Diseases

              Details:

              Thykamine (PUR0110) is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders.

              Lead Product(s): Thykamine

              Therapeutic Area: Dermatology Product Name: PUR0110

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 12, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Devonian Health Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Devonian Health Group Announces Peer-Reviewed Publication of Thykamine™ Positive Phase 2 Clinical Trial Results in Journal of Drugs in Dermatology

              Details:

              In the study, a significantly greater proportion of adult patients treated with Thykamine™ (PUR0110) cream 0.10% achieved an IGA of clear/almost clear and at least a 2-grade improvement from baseline in IGA (30.8%) compared to placebo (6.7%; P =.014).

              Lead Product(s): Thykamine

              Therapeutic Area: Dermatology Product Name: PUR0110

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Devonian Health Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Devonian Health Group Announces the Journal of Drugs in Dermatology Acceptance for Publication of Thykamine™ Positive Phase 2 Clinical Trial Results in Atopic Dermatitis

              Details:

              The benefit of PUR0110 (Thykamine) cream 0.10% was supported by a statistically significant effect on the primary and secondary endpoints of Body Surface Area (BSA), pruritis, and Patient-Oriented Eczema Measure score (POEM).

              Lead Product(s): Thykamine

              Therapeutic Area: Dermatology Product Name: PUR0110

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 26, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Devonian Health Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Devonian Health Group Announces Positive Topline Results from Phase 2 Clinical trial of Thykamine™ in Mild to Moderate AD

              Details:

              According to the results from the study, Thykamine at 0.1% showed significant improvement in skin clearance versus placebo at all measured timelines, thereby meeting the primary endpoint. It showed a fast onset of the therapeutic effect.

              Lead Product(s): Thykamine

              Therapeutic Area: Dermatology Product Name: PUR0110

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: PurGenesis Technologies

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Devonian Health Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Devonian Health Group Reports Notice of Allowance for a US Patent Application Covering Use of Thykamine for Ulcerative Colitis

              Details:

              Devonian announced that the US Patent and Trademark Office has issued a Notice of Allowance for patent titled “Thylakoid Extract Composition and Formulation for the Treatment of Inflammatory Bowel Disease" covering the use of Thykamine™ for the treatment of Ulcerative Colitis.

              Lead Product(s): Thylakoid extract

              Therapeutic Area: Gastroenterology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 15, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY